Precision BioSciences, Inc.
Moat Score — Precision BioSciences, Inc.
Total Moat Score
8 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Precision BioSciences' ARCUS platform is a proprietary, patented, single-protein gene editor licensed from Duke University since 2006, with a genuinely differentiated guide-RNA-free, compact design that is harder to replicate than a typical CRISPR variant. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | ARCUS's small size could eventually lower AAV manufacturing costs relative to bulkier multi-component editing systems if a product reaches commercialization, but today the company has no revenue and no realized cost advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 0 / 5 | With no approved products, Precision BioSciences has no current pricing power; any future pricing power is entirely contingent on clinical success in a crowded gene-editing field. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | There is no network effect in a clinical-stage gene editing company; value is driven by clinical data, platform IP, and partnerships, not user or data network dynamics. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | With no commercial products, there are no patient-level switching costs yet; however, the loss of the Novartis partnership in January 2026 shows that even pharma-partner relationships carry limited switching friction when a collaborator decides to exit. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | Gene editing for rare, genetically-defined diseases like DMD and chronic HBV supports a limited number of well-capitalized platform companies, giving Precision BioSciences some protection from a flood of new entrants even as it competes with seven or more established peers. |